50mg vial with 3ml bac water included
Quanta Pharma Retatrutide 50 mg is a triple agonist peptide that targets GLP-1, GIP, and glucagon receptors. It is investigated for its combined effects on insulin regulation, energy metabolism, and appetite signalling, with research interest in its potential role in weight and metabolic control. Laboratory testing reports a purity of 99.84%.
Research focus includes:
Triple receptor activity — engages GLP-1, GIP, and glucagon pathways in metabolic studies
Metabolic regulation — examined for effects on insulin sensitivity and glucose handling
Energy expenditure — studied for its potential role in increasing metabolic rate and lipid utilisation
Appetite signalling — explored for influence on satiety and food intake regulation
Pharmacokinetics — characterised by an extended half-life supporting once-weekly research protocols
